Denali Therapeutics (DNLI) Income towards Parent Company (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Income towards Parent Company data on file, last reported at -$128.4 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$128.4 million, up 3.4% year-over-year; the trailing twelve-month figure through Mar 2026 was -$507.9 million (down 11.91% YoY), and the FY2025 annual result was -$512.5 million, down 21.23% from the prior year.
• Income towards Parent Company was little changed at -$128.4 million in Q1 2026 per DNLI's latest filing, from -$128.4 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $183.4 million in Q2 2023 and troughed at -$133.0 million in Q1 2025.
• A 5-year average of -$90.4 million and a median of -$107.2 million in 2024 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2023 and 2024: Income towards Parent Company jumped 411.91% in 2023, then tumbled 154.0% in 2024.
• A 5-year view of Income towards Parent Company shows it stood at -$98.7 million in 2022, then slipped by 21.07% to -$119.5 million in 2023, then rose by 4.01% to -$114.7 million in 2024, then fell by 12.0% to -$128.4 million in 2025, then changed by 0.0% to -$128.4 million in 2026.
• Business Quant data shows DNLI's Income towards Parent Company at -$128.4 million in Q1 2026, -$128.4 million in Q4 2025, and -$126.9 million in Q3 2025.